-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It's been 15 years since the first large-scale study of psoriasis accelerated myocardial infarction ri.
For every 10% increase in body surface area affected by psoriasis, regardless of body mass index, the risk of developing diabetes increases by 20%
Dyslipidemia, defined as elevated low-density lipoprotein (LDL) and triglycerides or reduced high-density lipoprotein, is highly prevalent in psoriasis; increases with increased body surface area affected by psoriasis; is a variety of systemic Drivers of co-morbid conditions, including stroke, heart attack, and fatty liver disea.
Identifying psoriasis as an increased cardiovascular risk factor
Treatment with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or statins has been the cornerstone of the treatment of dyslipidemia associated with atherosclerotic cardiovascular disea.
Recently, statins were shown to be beneficial in lowering blood lipids and reducing cardiovascular events in patients with psoriasis compared with non-psoriatic patients, and in another post-analysis, statins were shown to improve outcomes in patients with psoriasis Low density lipoprotein leve.
First, studies have shown that the aggregated score of the venous endothelial cell transcriptome, although not associated with statin biomarkers or risk factors, is a favorable response to statin therapy, beyond those for which statins are generally not clinically applicable adjustment for cardiovascular risk factors in patien.
Source: Mehta NN, Gelfand JM, Is It Prime Time for Statin Therapy in Psoriasis? J Invest Dermatol 2022 Jun;142(6)
leave a message here
